Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma: A dose-finding study

M. Reni, S. Cereda, E. Bonetto, M. G. Viganô, P. Passoni, A. Zerbi, G. Balzano, R. Nicoletti, C. Staudacher, V. Di Carlo

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The aim of this study was to assess the maximum tolerated dose (MTD) of an intensified PEFG regimen administered every 14 days to patients with Stage III or metastatic pancreatic adenocarcinoma. Twenty-nine patients received fixed doses of both epirubicin (30 mg/m2) and 5-fluorouracil (200 mg/m2/day on Days 1-14) and of escalating doses of cisplatin and gemcitabine. The MTD was cisplatin 30 mg/m2 and gemcitabine 800 mg/m2. With respect to classical PEFG, intensified regimen potentially improved the dose-intensity of both cisplatin and epirubicin by 50 percent and of gemcitabine by 33 percent, reduced Grade 3-4 haematological toxicity and the number of outpatient accesses.

Original languageEnglish
Pages (from-to)594-598
Number of pages5
JournalCancer Investigation
Volume25
Issue number7
DOIs
Publication statusPublished - Oct 2007

Fingerprint

gemcitabine
Epirubicin
Fluorouracil
Cisplatin
Adenocarcinoma
Maximum Tolerated Dose
Outpatients

Keywords

  • 5-Fluorouracil
  • Chemotherapy
  • Cisplatin
  • Epirubicin
  • Gemcitabine
  • Metastatic disease
  • Pancreatic cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma : A dose-finding study. / Reni, M.; Cereda, S.; Bonetto, E.; Viganô, M. G.; Passoni, P.; Zerbi, A.; Balzano, G.; Nicoletti, R.; Staudacher, C.; Carlo, V. Di.

In: Cancer Investigation, Vol. 25, No. 7, 10.2007, p. 594-598.

Research output: Contribution to journalArticle

Reni, M. ; Cereda, S. ; Bonetto, E. ; Viganô, M. G. ; Passoni, P. ; Zerbi, A. ; Balzano, G. ; Nicoletti, R. ; Staudacher, C. ; Carlo, V. Di. / Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma : A dose-finding study. In: Cancer Investigation. 2007 ; Vol. 25, No. 7. pp. 594-598.
@article{d62dbe65150e4fc3bb80efaee4280572,
title = "Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma: A dose-finding study",
abstract = "The aim of this study was to assess the maximum tolerated dose (MTD) of an intensified PEFG regimen administered every 14 days to patients with Stage III or metastatic pancreatic adenocarcinoma. Twenty-nine patients received fixed doses of both epirubicin (30 mg/m2) and 5-fluorouracil (200 mg/m2/day on Days 1-14) and of escalating doses of cisplatin and gemcitabine. The MTD was cisplatin 30 mg/m2 and gemcitabine 800 mg/m2. With respect to classical PEFG, intensified regimen potentially improved the dose-intensity of both cisplatin and epirubicin by 50 percent and of gemcitabine by 33 percent, reduced Grade 3-4 haematological toxicity and the number of outpatient accesses.",
keywords = "5-Fluorouracil, Chemotherapy, Cisplatin, Epirubicin, Gemcitabine, Metastatic disease, Pancreatic cancer",
author = "M. Reni and S. Cereda and E. Bonetto and Vigan{\^o}, {M. G.} and P. Passoni and A. Zerbi and G. Balzano and R. Nicoletti and C. Staudacher and Carlo, {V. Di}",
year = "2007",
month = "10",
doi = "10.1080/07357900701359932",
language = "English",
volume = "25",
pages = "594--598",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma

T2 - A dose-finding study

AU - Reni, M.

AU - Cereda, S.

AU - Bonetto, E.

AU - Viganô, M. G.

AU - Passoni, P.

AU - Zerbi, A.

AU - Balzano, G.

AU - Nicoletti, R.

AU - Staudacher, C.

AU - Carlo, V. Di

PY - 2007/10

Y1 - 2007/10

N2 - The aim of this study was to assess the maximum tolerated dose (MTD) of an intensified PEFG regimen administered every 14 days to patients with Stage III or metastatic pancreatic adenocarcinoma. Twenty-nine patients received fixed doses of both epirubicin (30 mg/m2) and 5-fluorouracil (200 mg/m2/day on Days 1-14) and of escalating doses of cisplatin and gemcitabine. The MTD was cisplatin 30 mg/m2 and gemcitabine 800 mg/m2. With respect to classical PEFG, intensified regimen potentially improved the dose-intensity of both cisplatin and epirubicin by 50 percent and of gemcitabine by 33 percent, reduced Grade 3-4 haematological toxicity and the number of outpatient accesses.

AB - The aim of this study was to assess the maximum tolerated dose (MTD) of an intensified PEFG regimen administered every 14 days to patients with Stage III or metastatic pancreatic adenocarcinoma. Twenty-nine patients received fixed doses of both epirubicin (30 mg/m2) and 5-fluorouracil (200 mg/m2/day on Days 1-14) and of escalating doses of cisplatin and gemcitabine. The MTD was cisplatin 30 mg/m2 and gemcitabine 800 mg/m2. With respect to classical PEFG, intensified regimen potentially improved the dose-intensity of both cisplatin and epirubicin by 50 percent and of gemcitabine by 33 percent, reduced Grade 3-4 haematological toxicity and the number of outpatient accesses.

KW - 5-Fluorouracil

KW - Chemotherapy

KW - Cisplatin

KW - Epirubicin

KW - Gemcitabine

KW - Metastatic disease

KW - Pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=36248954607&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36248954607&partnerID=8YFLogxK

U2 - 10.1080/07357900701359932

DO - 10.1080/07357900701359932

M3 - Article

C2 - 17852117

AN - SCOPUS:36248954607

VL - 25

SP - 594

EP - 598

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 7

ER -